| Type of support |
Approvals 2001-2023 (US$)(23 May 2019) |
Commitments 2001-2023 (US$)(23 May 2019) |
Disbursements 2000-2019 (US$)(23 May 2019) |
% Disbursed(23 May 2019) |
2001 |
2002 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|
|
| Total |
$128,918,840 |
$136,853,980 |
$118,233,874 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash support (CASHSUPP) |
$170,000 |
$195,000 |
$170,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$7,468,586 |
$7,468,586 |
$7,427,786 |
99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$8,913,360 |
$14,560,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV (NVS) |
$4,102,306 |
$6,104,806 |
$3,085,406 |
75% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$240,095 |
$240,095 |
$240,095 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC (NVS) |
$6,087,189 |
$6,087,189 |
$6,087,189 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV MAC - Op costs (OPC) |
$385,626 |
$385,626 |
$385,626 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$1,529,848 |
$1,529,848 |
$1,529,848 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$621,157 |
$666,657 |
$499,683 |
80% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$948,925 |
$948,925 |
$948,925 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$1,244,759 |
$1,244,759 |
$369,889 |
30% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles (NVS) |
$584,464 |
$799,964 |
$323,464 |
55% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Rubella (NVS) |
$3,785,235 |
$3,785,235 |
$3,785,235 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR - Operational costs (OPC) |
$3,407,312 |
$3,407,312 |
$3,407,312 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR-Follow-up campaign (NVS) |
$1,261,500 |
$1,261,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR-Follow-up campaign op.costs (OPC) |
$1,157,417 |
$1,157,417 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$29,634,490 |
$29,634,490 |
$29,673,795 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$43,825,052 |
$43,825,052 |
$46,660,244 |
106% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Product Switch Grant (PSG) |
$121,928 |
$121,928 |
$121,928 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$11,002,075 |
$11,002,075 |
$11,079,733 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCV - Outbreak op. costs (OPC) |
$202,150 |
$202,150 |
$202,150 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCV Outbreak (NVS) |
$510,000 |
$510,000 |
$520,200 |
102% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$1,715,366 |
$1,715,366 |
$1,715,366 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format